secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001437749-26-008511
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data
--------------------------------------------------------------------------------

- 100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).
- Reducing headcount in sales/marketing; redirecting resources to cardiac catheter program and pivotal IDE study.
- Streamlining soft-tissue ablation to focus on benign thyroid nodules and real-world data.
- Late-breaking 12-month follow-up data to be presented at Heart Rhythm 2026 on April 25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926008511/0001437749-26-008511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926008511/plse20260316c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-008511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer